Pharming Group PHAR
$11.54 −$0.63 (-5.18%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $11.54 0.00%
Open$11.85
Prev close$12.17
Day range$11.30 – $11.97
Volume10.5K
Market cap$816.78M
P/E (TTM)35.0
Dividend yield–
Earnings
Average move on report day±8.6%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+12.9%
Worst reaction-26.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 27 Oct 2026 | Pre Market | – | -0.25% | – |
| 2026/Q2 | 30 Jul 2026 | Pre Market | – | -10.49% | – |
| 2026/Q1 | 7 May 2026 | Pre Market | – | -26.83% | – |
| 2025/Q4 | 12 Mar 2026 | Pre Market | – | -4.66% | – |
| 2025/Q3 | 6 Nov 2025 | Pre Market | – | +11.53% | – |
| 2025/Q2 | 31 Jul 2025 | Pre Market | – | +10.11% | – |
| 2025/Q1 | 8 May 2025 | None | – | +11.22% | – |
| 2024/Q4 | 13 Mar 2025 | Pre Market | – | +12.92% | – |
| 2024/Q3 | 24 Oct 2024 | None | – | -7.37% | – |
| 2024/Q2 | 1 Aug 2024 | None | – | -8.40% | – |
| 2024/Q1 | 8 May 2024 | None | – | -1.66% | – |
| 2023/Q4 | 14 Mar 2024 | None | – | -1.71% | – |
| 2023/Q3 | 26 Oct 2023 | Pre Market | – | +5.00% | – |
| 2023/Q2 | 3 Aug 2023 | None | – | +4.17% | – |
| 2023/Q1 | 11 May 2023 | None | – | -20.36% | – |
| 2022/Q4 | 16 Mar 2023 | None | – | -1.56% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q1
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$117.56M+20.8% YoY
Operating profit$27.59M+75.2% YoY
Net profit$22.43M+197.1% YoY
Diluted EPS$0.32+188.1% YoY
Free cash flow$32.09M+0.4% YoY
Operating cash flow$32.37M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin85.1%
Operating margin6.7%
Net margin6.3%
Return on equity8.7%
Return on assets5.0%
Return on invested capital6.0%
Current ratio3.23
Liabilities / assets41.4%
Cash & investments$189.56M
Total debt$111.03M
Net cash (debt)$78.53M
Free cash flow / sales8.9%
No comments yet — be the first to weigh in on PHAR.
Sign in to join the discussion.